[{"orgOrder":0,"company":"LipoMedix","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Promitil","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"LipoMedix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"LipoMedix \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"LipoMedix \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tucatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tesetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Public Offering","leadProduct":"Tesetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Jefferies","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Elion Oncology","sponsor":"Processa Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Eniluracil","moa":"DPD","graph1":"Oncology","graph2":"Phase I","graph3":"Elion Oncology","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Oral","sponsorNew":"Elion Oncology \/ Processa Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Elion Oncology \/ Processa Pharmaceuticals"},{"orgOrder":0,"company":"Knight Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Knight Therapeutics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Knight Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Knight Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"CStone Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Sugemalimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"CStone Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CStone Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"CStone Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tesetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Zai Lab","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Zai Lab","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Zai Lab \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Zai Lab \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Trastuzumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0.28000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.28000000000000003,"dosageForm":"Oral","sponsorNew":"Seagen \/ Merck","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Merck"},{"orgOrder":0,"company":"Odonate Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tesetaxel","moa":"Tubulin","graph1":"Oncology","graph2":"Phase III","graph3":"Odonate Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Odonate Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Odonate Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Neratinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Puma Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"MacroGenics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Margetuximab","moa":"HER2\/Neu receptor","graph1":"Oncology","graph2":"Approved","graph3":"MacroGenics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"MacroGenics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"MacroGenics \/ Not Applicable"},{"orgOrder":0,"company":"ForDoz","sponsor":"LipoMedix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"ForDoz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ForDoz \/ LipoMedix","highestDevelopmentStatusID":"8","companyTruncated":"ForDoz \/ LipoMedix"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Capecitabine","moa":"DNA","graph1":"Oncology","graph2":"Approved","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Not Applicable"},{"orgOrder":0,"company":"ForDoz","sponsor":"LipoMedix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"ForDoz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"ForDoz \/ LipoMedix","highestDevelopmentStatusID":"8","companyTruncated":"ForDoz \/ LipoMedix"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Capecitabine","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zymeworks \/ Not Applicable"},{"orgOrder":0,"company":"Seagen","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tucatinib","moa":"HER2 tyrosine kinase","graph1":"Oncology","graph2":"Approved","graph3":"Seagen","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Seagen \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Seagen \/ Not Applicable"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Capecitabine","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase II","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Zymeworks \/ Not Applicable"},{"orgOrder":0,"company":"Vector Pharma","sponsor":"R-Pharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Ixabepilone","moa":"Tubulin","graph1":"Oncology","graph2":"Approved","graph3":"Vector Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vector Pharma \/ R-PHARM","highestDevelopmentStatusID":"12","companyTruncated":"Vector Pharma \/ R-PHARM"},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Zymeworks \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"Zymeworks \/ BeiGene"},{"orgOrder":0,"company":"Zymeworks","sponsor":"BeiGene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"HER2 receptor","graph1":"Oncology","graph2":"Phase III","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zymeworks \/ BeiGene","highestDevelopmentStatusID":"10","companyTruncated":"Zymeworks \/ BeiGene"},{"orgOrder":0,"company":"Zymeworks","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"HER2 signal","graph1":"Oncology","graph2":"Phase III","graph3":"Zymeworks","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Zymeworks \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Zymeworks \/ Not Applicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Epizyme","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"Claudin18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Epizyme","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Epizyme"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Sintilimab","moa":"PD-1","graph1":"Oncology","graph2":"Approved","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"12","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"Claudin18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Not Applicable"},{"orgOrder":0,"company":"Dizal Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Dizal Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Dizal Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Dizal Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"Claudin18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Not Applicable"},{"orgOrder":0,"company":"Puma Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Neratinib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Puma Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Puma Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Puma Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Genentech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Genentech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genentech \/ Not Applicable"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cyteir Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Jazz Pharmaceuticals","sponsor":"Zymeworks","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Jazz Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Jazz Pharmaceuticals \/ Zymeworks","highestDevelopmentStatusID":"10","companyTruncated":"Jazz Pharmaceuticals \/ Zymeworks"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"ARX788","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"BeiGene","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tislelizumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"BeiGene","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BeiGene \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"BeiGene \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Transcenta Holding","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Transcenta Holding \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Transcenta Holding \/ Not Applicable"},{"orgOrder":0,"company":"CARsgen Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"AB011","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"CARsgen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CARsgen Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CARsgen Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Ambrx Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Public Offering","leadProduct":"ARX788","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Ambrx Inc","amount2":0.080000000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Infusion","sponsorNew":"Ambrx Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Ambrx Inc \/ Undisclosed"},{"orgOrder":0,"company":"Cyteir Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rad51-IN-2","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Cyteir Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Cyteir Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Cyteir Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Compugen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Compugen","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.20999999999999999,"dosageForm":"Infusion","sponsorNew":"Compugen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Compugen \/ AstraZeneca"},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Cadonilimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Akeso \/ Not Applicable"},{"orgOrder":0,"company":"Chugai Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Chugai Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Chugai Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Chugai Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Compugen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Compugen","amount2":0.20999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.20999999999999999,"dosageForm":"Infusion","sponsorNew":"Compugen \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Compugen \/ AstraZeneca"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Eniluracil","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"H.C. Wainwright & Co.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Public Offering","leadProduct":"Eniluracil","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ H.C. Wainwright & Co.","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ H.C. Wainwright & Co."},{"orgOrder":0,"company":"CrystalGenomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"CG200745","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"CrystalGenomics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CrystalGenomics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"CrystalGenomics \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Arcus Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Gilead Sciences \/ Arcus Biosciences","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Arcus Biosciences"},{"orgOrder":0,"company":"Arcus Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Arcus Biosciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Arcus Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"10","companyTruncated":"Arcus Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"GSK","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Dostarlimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"GSK","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"GSK \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"GSK \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Eniluracil","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Beijing Biostar Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Beijing Biostar Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Beijing Biostar Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Beijing Biostar Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Eniluracil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Astellas Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Processa Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Eniluracil","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Processa Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Processa Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Processa Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Akeso","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Cadonilimab","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Akeso","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Akeso \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Akeso \/ Not Applicable"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"F. Hoffmann-La Roche \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"F. Hoffmann-La Roche \/ Not Applicable"},{"orgOrder":0,"company":"Astellas Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Capecitabine","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"Astellas Pharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"Astellas Pharma \/ Not Applicable","highestDevelopmentStatusID":"14","companyTruncated":"Astellas Pharma \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals for pentyl N-{1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl}carbamate
Details :
Vyloy (zolbetuximab) is a chimeric IgG1 monoclonal antibody that binds to CLDN18.2. It is being evaluated for HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Details :
Vyloy (zolbetuximab), a CLDN 18.2 inhibitor has been approved in combination with chemotherapy for patients with HER2-negative, CLDN18.2 positive, unresectable, advanced or recurrent gastric cancer.
Details :
PCS6422 is an analog of uracil that irreversibly inhibits dihydropyrimidine dehydrogenase (DPD) enzyme, being developed for the treatment of breast cancer.
Details :
Cadonilimab, a novel bispecific antibody targets PD-1 and CTLA-4 has been approved in combination with chemotherapy for locally advanced unresectable or metastatic G/GEJ adenocarcinoma.
Details :
Vyloy (zolbetuximab) is a chimeric IgG1 monoclonal antibody that binds to CLDN18.2. It is being evaluated for HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Details :
PCS6422 is an analog of uracil that irreversibly inhibits dihydropyrimidine dehydrogenase (DPD) enzyme, being developed for the treatment of breast cancer.
Details :
Vyloy (zolbetuximab) is a chimeric IgG1 monoclonal antibody that binds to CLDN18.2. It is being evaluated for HER2-negative gastric or gastroesophageal junction adenocarcinoma.
Details :
UTD1 (utidelone) is an investigational tubulin inhibitor, given intravenously in combination with capecitabine for its potential efficacy in patients with HER2-negative breast cancer brain metastases.
Details :
NGC-Cap is PCS6422 (eniluracil) administered in combination with capecitabine, a precursor of the cancer drug 5-FU. It is being evaluated for the treatment of gastrointestinal cancer.
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
